WISEMAN¹, 2002 - Google Patents
Soy and mechanisms of vascular protectionWISEMAN¹, 2002
- Document ID
- 17993791225575078356
- Author
- WISEMAN¹ H
- Publication year
- Publication venue
- Soy & Health 2002: Clinical Evidence, Dietetic Applications
External Links
Snippet
Although cholesterol lowering is probably the best-documented cardioprotective effect of soy (Sirtori and Lovati, 2001, Clarkson 2002), vascular protection is also likely to contribute and may be mediated via a number of mechanisms including antioxidant action, effects on …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wroblewski Lissin et al. | Phytoestrogens and cardiovascular health | |
| Kaliora et al. | Natural antioxidant compounds in risk factors for CVD | |
| Ranich et al. | Protective effects of dietary phytoestrogens in chronic renal disease | |
| Setchell et al. | Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements | |
| RU2303373C2 (en) | Compositions and methods for improving the state of vascular system | |
| Sen et al. | Tocotrienols: the emerging face of natural vitamin E | |
| Isanga et al. | Soybean bioactive components and their implications to health—a review | |
| US20040048919A1 (en) | Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects | |
| Zhou et al. | Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice | |
| Thiagarajan et al. | Prevention of precancerous colonic lesions in rats by soy flakes, soy flour, genistein, and calcium | |
| US5498631A (en) | Method for treatment of menopausal and premenstrual symptoms | |
| Hasler | The cardiovascular effects of soy products | |
| KR100741724B1 (en) | Hydroxymatairesinol in cancer prevention | |
| US20030144219A1 (en) | Formulations and methods for treatment or amelioration of inflammatory conditions | |
| Kurzer et al. | Fecal lignan and isoflavonoid excretion in premenopausal women consuming flaxseed powder. | |
| Bacciottini et al. | Phytoestrogens: food or drug | |
| Faraj et al. | Soybean isoflavones: effects of processing and health benefits | |
| WO2001003687A2 (en) | Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans | |
| Huang et al. | Cholesterol-lowering activity of soy-derived glyceollins in the golden Syrian hamster model | |
| Fang et al. | Effect of genistein supplementation on tissue genistein and lipid peroxidation of serum, liver and low-density lipoprotein in hamsters | |
| Salgado et al. | Soy as a functional food | |
| Cassidy | Dietary phyto-oestrogens: molecular mechanisms, bioavailability and importance to menopausal health | |
| WISEMAN¹ | Soy and mechanisms of vascular protection | |
| Yagiz et al. | Potential health promoting properties of isoflavones, saponins, proanthocyanidins, and other phytonutrients in pulses | |
| Button et al. | Phytoestrogens for osteoporosis |